The Cellularis Discovery by Early Sight
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $25,000 to $250,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- Points of contact
-
- Joshua Holliday joshua.holliday@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Department of Health and Human Services Food and Drug Administration (FDA) is forecasting a procurement for the Cellularis Discovery by Early Sight, a commercial clinical AO retinal camera designed to advance the development of new cellular imaging biomarkers for the Ophthalmic Devices Program. This new requirement is estimated to have a solicitation release date of April 1, 2026, with an anticipated award date of June 1, 2026, targeting the Analytical Laboratory Instrument Manufacturing sector (NAICS 334516). The contract aims to foster clinical translation of innovative medical device technology by developing new methods and tools using this advanced imaging system.
While specific award values are not provided, the opportunity is being managed by Joshua Holliday (joshua.holliday@fda.hhs.gov) from the FDA, who will likely serve as the primary point of contact for potential vendors. The contract appears to be unrestricted, with no specific set-aside designation, suggesting open competition among qualified manufacturers and technology providers in the medical imaging field. Additional detailed information about budget ranges, exact quantities, or precise performance locations was not available in the forecast documentation.
Forecast text
The Cellularis Discovery by Early Sight is one of the first commercial clinical AO retinal cameras. It will be used to advance the development of new cellular imaging biomarkers for the Ophthalmic Devices Program. In particular, many new methods and tools will be developed using this system. It fulfills the FDA mission to foster clinical translation of innovative medical device technology.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast